Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PFKFB3 | Q16875 | 4/20 | 0.41 |
| ▸ | PFKFB4 | Q16877 | 4/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tianafac SCHEMBL2109723 | 0.84 | MAPT (0.67) | MAPTPFKFB3PFKFB4KEAP1NFE2L2 | |
| SCHEMBL10091955 | 0.73 | MAPT (0.56) | MAPTPFKFB3PFKFB4ROCK1CMA1 | |
| SCHEMBL14435191 | 0.72 | MAPT (0.56) | MAPTPFKFB3PFKFB4KEAP1NFE2L2 | |
| SCHEMBL11256326 | 0.71 | MAPT (0.54) | MAPTPFKFB3PFKFB4ROCK1CMA1 | |
| SCHEMBL6984802 | 0.71 | MAPT (0.54) | MAPTPFKFB3PFKFB4ROCK1CMA1 | |
| SCHEMBL122587 | 0.70 | GPR35 (0.58) | MAPTPFKFB3PFKFB4ROCK1CMA1 | |
| SCHEMBL14218140 | 0.70 | MAPT (0.54) | MAPTNPSR1 | |
| SCHEMBL1253215 | 0.69 | MAPT (0.56) | MAPTPFKFB3PFKFB4ROCK1CMA1 | |
| SCHEMBL1253216 | 0.69 | MAPT (0.52) | MAPTPFKFB4ROCK1CMA1NPSR1 | |
| Hydrochloric Acid SCHEMBL9050783 | 0.69 | MAPT (0.49) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | MAPT 4719/4885PFKFB3 2877/4885PFKFB4 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.